Product Datasheet
|
Catalog Number |
ADT1005 |
|
Product Name |
Abciximab Research Biosimilar |
|
Product Description |
Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitionitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. |
|
CAS Number |
143653-53-6 |
|
Chemical Formula |
C6462H9964N1690O2049S48 |
|
Clonity |
Monoclonal |
|
Target |
ITGA2B_ITGB3[Homo sapiens] |
|
Alias |
c7E3, Abciximab Research Biosimilar |
|
Host |
CHO Cells |
|
Isotype |
Fab-G1 Kappa |
|
Size |
1mg,5mg |
|
Molecular Weight |
145.65 KDa |
|
Mechanism of Action |
Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. By binding to the vitronectin receptor (also known as the αvβ3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.
|
|
Metabolism |
Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production. Excreted renally. |
|
Buffer |
Supplied in PBS, PH7.5 |
|
Concentration |
Batch dependent, please contact our customer service to get the COAs of current batch |
|
Purity |
>95% as determined by SDS-PAGE |
|
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
|
Shipping Condition |
This product is shipped in blue ice. |
.jpg){kind=logo}
